Description
A meta-analysis of 12 randomized controlled trials found that combining vildagliptin with metformin offers effective glycemic control and favorable safety in patients with type 2 diabetes mellitus (T2DM). Compared to metformin alone or with placebo, the combination demonstrated superior reductions in HbA1c with similar safety outcomes. When compared with metformin plus other oral hypoglycemic agents, efficacy in HbA1c reduction was comparable across all durations. However, after more than 52 weeks of treatment, the vildagliptin–metformin combination showed a superior safety profile, with fewer hypoglycemic episodes and adverse events. The findings highlight the combination’s value as a long-term therapeutic option for T2DM management.